Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Fragment Based Lead Discovery

Chun-Wa Chung's Biography

Chun-Wa Chung, Research Manager, GlaxoSmithKline

o Structural biophysicist
o BA degree in Natural Science (University of Cambridge UK)
o PHD in NMR method development (Department of Chemistry in Cambridge).
o Joined GlaxoSmithKline as a temporary postdoctoral researcher and never left.
o Currently lead group that spans Xray crystallography, NMR and biophysics at GSK’s UK research site in Stevenage, which matches personal expertise in these areas.
o Group supports biophysical MOA to fragment screening and crystallography across a wide range of therapeutic areas.
o Current personal research focus is epigenetics (epi-reader and epi-enzyme).

Chun-Wa Chung Image

Hedging Your BETs – The Benefit of Phenotypic and Fragment approaches

Wednesday, 14 March 2012 at 16:15

Add to Calendar ▼2012-03-14 16:15:002012-03-14 17:15:00Europe/LondonHedging Your BETs – The Benefit of Phenotypic and Fragment

This presentation describes the use of phenotypic and fragment based approaches to identify protein-protein inhibitors that disrupt the interaction between BET bromodomains and chromatin, and the benefits of exploring novel target classes using these disparate methods.

Add to Calendar ▼2012-03-13 00:00:002012-03-14 00:00:00Europe/LondonFragment Based Lead